Novartis Files Application for Macular Degeneration Treatment

Date : 04/15/2019 @ 10:46PM
Source : Dow Jones News
Stock : Novartis Ag (NVS)
Quote : 75.9  0.5 (0.66%) @ 1:00AM

Novartis Files Application for Macular Degeneration Treatment

Novartis (NYSE:NVS)
Historical Stock Chart

1 Month : From Mar 2019 to Apr 2019

Click Here for more Novartis Charts.

By Patrick Thomas

 

Novartis International AG (NVS) said Monday that the U.S. Food and Drug Administration accepted its biologics license application for brolucizumab, an experimental treatment for wet age-related macular degeneration.

Novartis said the FDA is evaluating the treatment in a priority review, and if approved, brolucizumab could hit the U.S. market by year's end.

Novartis said its application was based on clinical data from late-stage efficacy and safety trials of intravitreal injections of brolucizumab.

The company said the tests showed significantly fewer patients treated with brolucizumab had disease activity and retinal fluid compared with patients treated with Regeneron Pharmaceuticals Inc.'s (REGN) aflibercept, also known as Eylea.

 

Write to Patrick Thomas at patrick.thomas@wsj.com

 

(END) Dow Jones Newswires

April 15, 2019 17:31 ET (21:31 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest NVS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.